Barrett’s Esophagus: Where Do We Stand?

Majid A. Al Madi

ABSTRACT

Barrett’s esophagus (BE) is a precursor for esophageal adenocarcinoma, which has an increased incidence rate over the last few decades. Its importance stems from the poor five-year survival of esophageal adenocarcinoma and current data that suggest a survival benefit when surveillance programs are implemented. In this review, we will cover the pathophysiology and natural history of BE and the different endoscopic findings. The prevalence of BE in different geographic areas and the incidence of high-grade dysplasia and adenocarcinoma in this patient population is reviewed. Recent recommendation for screening and surveillance of BE has been covered in this review as well as the efficacy of nonconventional imaging modalities and endoscopic ablation therapies.

Key Words: Ablation, Barrett’s esophagus, cancer, chemoprevention, dysplasia, esophagus, guidelines, imaging, screening, surveillance

Esophageal cancer incidence has rapidly accelerated over the last few decades with incidence rates in western countries surpassing other cancers like breast and prostate cancer.[1] Special attention is being paid to Barrett’s esophagus (BE) as it has been recognized as a precursor for esophageal adenocarcinoma (EAC). The latest guidelines from the American College of Gastroenterology have redefined BE as “a change in the distal esophageal epithelium of any length that can be recognized as columnar type mucosa at endoscopy and is confirmed to have intestinal metaplasia by biopsy of the tubular esophagus”[2] whereas the previous definition cited the “displacement of the squamocolumnar junction proximal to the gastroesophageal junction and endoscopy with multiple systematic biopsies needed to establish the diagnosis of Barrett’s esophagus.”[3] Intestinal metaplasia (IM) is clearly cited as a prerequisite to make the diagnosis in the more recent definition of BE. In addition, surveillance programs have been implicated for this patient population to detect high-grade dysplasia (HGD) or early adenocarcinoma with the hope of improving survival rates.

PATHOPHYSIOLOGY

The development of BE occurs in response to oxidative damage and inflammation inflicted on the mucosa from contact with the gastric contents. The end result of this cascade is metaplasia of the normal squamous lining of the esophagus to intestinal-type columnar epithelium that has the potential to develop EAC. There is definite genetic predisposition to the development of BE, as it has been demonstrated that there is an increase in the risk of EAC in patients with GERD or BE carrying the genotypes for epidermal growth factor (EGF) A61G G/G, cyclooxygenase 2 (COX2) 8473 C.[4,5] Also an animal study suggested that multipotent progenitor cells of bone marrow origin may play a role in metaplasia in BE.[6] Multiple inflammatory mediators have become a target for researchers in the hope of decreasing the progression to adenocarcinoma, especially after studies demonstrated that superoxide dismutase and COX2 inhibitors decreased the progression of BE and adenocarcinoma in animal models of BE.[7-9] Of these mediators, secretory phospholipase A,[2] eicosanoid, COX2, prostaglandin E2 and leukotriene B4[10-12] have been targeted; the use of the n3 fatty acid eicosapentaenoic acid (EPA) has been shown to decrease COX2 protein concentration.[10] Also, aspirin in combination with a PPI was demonstrated to decrease the concentration of prostaglandin E2.(12) A meta-analysis demonstrated a protective effect of aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) from esophageal cancer,[13] whereas the use of COX2 inhibitors did not alter the natural history of BE in a number of randomized controlled trials (RCTs) including the Chemoprevention for BE Trial (CBET).[14,15] In addition, multiple intracellular signaling proteins that regulate EAC proliferation and apoptosis have been identified and targeted recently such as extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) using statins[16,17] as well as iron import proteins.[18]
NATURAL HISTORY

The prevalence of BE in patients with gastroesophageal reflux disease (GERD) has been reported to be about 10–20% in western countries\[19\] and about 0.2–5% in Asia.\[20-23\] The prevalence of BE in patients undergoing upper endoscopic procedures for any reason was found to be 2.1%.\[19,22\] Published data on the natural history of BE has been variable, with the prevalence of EAC in patients with BE in the range of 5%.\[21\] It has been noted that there is a difference in the prevalence of BE among different ethnicities and geographical areas, with a high prevalence in the western hemisphere and being less in blacks, Hispanics, and Asians.\[24-26\] A recent meta-analysis by Yousef et al\[27\] estimated the cancer risk in patients with BE to be 6.1/1000 person-years, and when early cancer and high-grade dysplasia (HGD) were excluded to be 4.1/1000 person-years and that men progressed to cancer at twice the rate when compared with women. A second meta-analysis showed that in patients with BE and HGD, the rate of developing adenocarcinoma was 6/100 person-years\[28\] and that rate did not differ on the basis of geographical areas.\[29\] Dietary habits have been associated with the risk of the development of BE, as the consumption of a western diet (rich in fast foods and meat) had an adverse effect on the development of BE, and an inverse relationship was found between BE and the consumption of fruits, vegetables, and nonfired fish.\[30\] Other risk factors identified for the development of BE are male gender, age more than 40 years, heartburn more than once per week, and long duration of symptoms (>13 years).\[21,31-36\] A recent meta-analysis addressed the issue of increased adiposity as a risk factor for developing BE and found that it had an indirect relationship through an increase in GERD rather than a direct effect.\[37\] Other causes of mortality apart from adenocarcinoma in patients with BE were bronchopneumonia and ischemic heart disease.\[38,39\]

Although Helicobacter pylori does not have any influence on esophageal acid reflux or on symptoms in patients with BE,\[40\] a meta-analysis demonstrated an inverse relationship between H. pylori infection and BE and esophageal adenocarcinoma, suggesting a protective effect of this infection.\[41,42\] This can explain to a degree the low prevalence of BE in areas with a high prevalence of H. pylori infection.

ENDOSCOPIC FINDINGS

BE is usually easily recognized with its typical salmon-colored mucosa that contrasts with the normal pearly white esophageal squamous mucosa. Also, BE is not appreciated on the index esophagogastroduodenoscopy (EGD), as it can be embedded within a background of inflammation in cases of erosive esophagitis in up to 12%. Thus, in such cases, the patient should be treated with a proton-pump inhibitor (PPI) and a repeat EGD to be performed at a latter date, at least at eight weeks, especially when the intention is screening for BE.\[43\] In addition, when endoscopic lesions are visible in a patient with known HGD, the risk of having EAC with invasion beyond the mucosa is higher than those without.\[44\] Conventionally, the length of BE lesions is measured by subtracting the distance from the incisors to the squamocolumnar junction from the distance from the incisors to the top of the gastric folds using the regular gastroscope. Even though this method has been demonstrated to be outperformed by gastroscopes marked at 1 cm as opposed to the traditional 5-cm intervals in the accuracy of measurements,\[45,46\] Another method for measuring the surface area of BE lesion size, designated as quantitative endoscopy (QE), was shown to be a safe and accurate way of following up BE lesions.\[47\] However, the recently developed and validated Prague C and M criteria for endoscopic diagnosis of BE has excellent landmark recognition of the squamocolumnar junction, gastroesophageal junction, the extent of circumferential columnar lining, and the most proximal extension of the columnar mucosa not accounting for islands of BE\[48\] and should be used as a standard method for describing BE. Although using methylene blue (MB) can selectively stain intestinal metaplasia, and the intensity of staining does correlate with the histological degree of dysplasia, it was not proven to be superior in the detection of dysplasia compared with the conventional four-quadrant biopsies (+4QB).\[49,52\]

PATHOLOGICAL FINDINGS

The histological findings on endoscopically obtained biopsies might be one of the most important facets that the management of BE hinges on. In BE, the normal squamous epithelium is substituted with glandular mucosa that is composed of metaplastic columnar cells and goblet cells with their distinct ovoid mucin droplets that can be identified by its blue staining reaction with Alcian blue and by the use of other immunohistochemical stains. Dysplasia, on the other hand, is defined as neoplastic epithelium that remains confined within the basement membrane of the epithelial surface within which it arose. Sampling error is a major concern in patients with BE, which stems from the observation that IM is a mosaic of three distinct epithelial patterns within the columnar lined esophagus and can be unifocal, multifocal, or diffuse.\[53\] In addition there is poor interobserver reproducibility of pathological grading of biopsies even where a high volume of BE patients are seen.\[54\] New methods that are used with the aim of assessing the prognosis of BE progressing to HGD or EAC are cytological studies, DNA ploidy analysis with digital image analysis, and fluorescence in situ hybridization. Although it has been demonstrated that the detection rate of IM is related to the number of biopsy obtained,\[55\] systematic 4QB was found to be more
effective than random biopsies. A technique for obtaining biopsies, coined, the “turn and suction” method results in a 56% longer biopsy specimen compared with the traditional method. Also, the use of an angled swing jaw forceps results in larger biopsy samples and a better quality of tissue obtained when compared with conventional forceps. With the advent of endoscopic ablation procedures for BE, histological regression, in addition to endoscopic regression, has been assessed as an endpoint for response to therapy. Histological regression of IM and dysplasia is seen as soon as one month after the application of ablation procedures as proven by immunohistochemistry, proliferative capacity, and DNA ploidy.

**SCREENING AND SURVEILLANCE**

As there is no current evidence that screening the general population for BE has an impact on the mortality from EAC, it has not been recommended at this point of time, and targeting populations at higher risk for BE are only recommended based on expert opinion and should be applied on an individual basis. The value of surveillance programs in patients with BE has been a point of debate. It could be argued to be worthwhile given the results of a database-derived study that demonstrated that when an EGD was performed one year prior to the diagnosis of EAC, the patients were diagnosed at an earlier stage and had improved survival rates. Furthermore, a second study found that when a surveillance program was applied in patients with BE, there was a 2% per year cure rate from cancer and a reduction in treatment costs. These programs would have a larger impact if patients at high risk for progression to HGD or EAC could be identified. When considering the initiation of a surveillance program for a patient with BE, it should be an informed decision with the understanding of the risks, benefits, limitations, and willingness to adhere to this process. Sampling of BE should be performed in a 4QB fashion every 2 cm and each segment submitted for pathology separately, so that focused biopsies can be performed if dysplasia is detected. When there is no dysplasia, a second EGD with biopsies should be performed within a year and then every three years. In the case of low-grade dysplasia (LG D), it should be confirmed by a gastrointestinal pathologist, and an EGD should be repeated after six months and then annually till two consecutive EGDs demonstrate no dysplasia. When HGD is detected on flat mucosa, it should be confirmed by an experienced gastrointestinal pathologist, and a repeat EGD performed within three months with 4 QBs at 1-cm intervals because of the risk of concomitant early EAC. If mucosal irregularity is found with HGD, endoscopic mucosal resection (EMR) should be performed and staging of the patient should be attempted because of the high risk of progression to EAC. The therapeutic options such as surgical, endoscopic ablation, and intense surveillance are presented to the patient at this time. Repeated surveillance is recommended after ablative procedures are performed if dysplasia is lost, as it has been demonstrated that HGD can recur, as well as the everlasting question of buried segments of Barrett’s mucosa as glands or islands under the neosquamous epithelium.

**MEDICAL VERSUS SURGICAL APPROACHES**

Although an initial study showed that a higher PPI dose resulted in better reduction of gastric pH in the normal population, in patients with BE, regardless of the PPI dose used, the gastric pH was >4 in 80–88% of patients, but the intraesophageal pH remained <4 for >5% of the time. Results from the LOTUS trial (a large multicenter randomized European study), with a three-year follow-up, showed that the esophageal pH was better controlled in patients with BE who underwent laparoscopic antireflux surgery (LARS), compared with patients treated with a PPI, but the symptom outcomes were the same. However, another study found that neither surgical nor medical management of patients with BE altered its natural history, and in a recent meta-analysis by Li et al, neither pharmacologic nor surgical antireflux measures achieved complete regression of BE, nor eliminated the risk of EAC. Two retrospective studies demonstrated a reduced risk of dysplasia when patients with BE used PPIs. Complex surgeries involving duodenal diversion procedures in addition to antireflux surgeries have been abandoned. Esophagectomy for early EAC in patients with BE still remains the standard of care, but this is associated with a high morbidity rate, and endoscopic ablative procedures are a viable option especially in high-risk patients. Factors that were found to be associated with patients undergoing an esophagectomy as opposed to endoscopic ablation procedures were age ≤ 60, cancer stage T1sm or greater, and initial consultation performed by a surgeon as opposed to a gastroenterologist. In cases with BE and HGD or early intramucosal adenocarcinoma (IMC), esophagectomy has been demonstrated to have excellent survival outcomes and low mortality rates. Also, vagal-sparing esophagectomy has been shown to have a less perioperative morbidity and a shorter hospital stay with less late complications such as weight loss, dumping, and diarrhea compared with transtiatal or en bloc esophagectomy.

**Endoscopic ablation techniques**

A large bulk of research in the field of BE has been devoted to the endoscopic prevention of progression of BE to adenocarcinoma or what is called endoprevention. Despite that a number of trials have been conducted for the different modalities for endoablation of BE, they had different endpoints, methodologies, and used different patient
populations of BE. The aim of these endoprevention techniques is the regression of Barrett’s mucosa to squamous reepithelialization. All of the studies incorporated acid suppressive therapy using either once daily or twice a day PPI. Argon plasma coagulation (APC) has been used to treat HGD and even small EAC lesions in a multicenter RCT. APC achieved regression of BE in 69–97% of patients. Similar results were obtained in an earlier study. Some of the complications of this treatment modality are dysphagia, strictures, chest pain, nausea, vomiting, and fever. As mentioned earlier, there is always a risk of recurrence even after regression of BE. Some of the factors that predict APC failure after initial reepithelialization are persistence of acid reflux and long segments of BE. Photodynamic therapy (PDT) is one of the earliest ablative techniques applied for BE, which utilizes different photosensitizing drugs followed by endoscopic laser light exposure of the segment of BE at a wavelength of 630 nm. The advantage of PDT is its ability to deliver a more targeted therapy and the capacity of giving repeated dosages. A large multicenter RCT demonstrated that PDT decreases the likelihood of high-grade dysplasia (HGD) [absolute risk reduction (ARR) of 38%], cancer (ARR 14%), and a longer time to progression to cancer in patients with BE. Similar results were found in a few earlier studies. Some of the side effects associated with PDT are cutaneous photosensitivity, odynophagia, and stricture formation. The risk of stricture formation was found to be related to the length of BE, the number of treatment sessions, previous strictures, and the use of EMR prior to PDT. Multipolar electrocoagulation (MPEC) was used in a RCT in a repeated fashion every four to eight weeks until endoscopic reversal of BE or up to six sessions, reversal of BE was achieved in 75–88% of patients. A meta-analysis demonstrated that endoscopic ablation for BE was capable of achieving endoscopic and histological reversal of BE, and APC appeared to be more effective than PDT, but there was no statistical difference between APC and MPEC. These studies were underpowered to detect a reduction or prevention of progression to adenocarcinoma. EMR has demonstrated good results for the treatment of patients with HGD and intramucosal adenocarcinoma (IMC) and demonstrated eradication of BE in 88% after a median follow-up of 28 months. Both the “inject, suck, and cut” and “band and snare” techniques yield equivalent and adequate depth of histological specimens. An advantage of using EMR in BE is the ability to stage superficial neoplasms when present in tandem with endoscopic ultrasound with good interobserver agreement when interpreting the specimens obtained. Circumferential balloon-based ablation using radiofrequency energy is a modality that has been proven to be safe and effective for ablation of BE with HGD with complete ablation of BE in 90% of patients after a median follow-up of 12 months. Also in another study, complete ablation was achieved in 98% of patients after 2.5 years. When compared with surgery, endoprevention is associated with a higher risk of progression of adenocarcinoma, whereas surgery has a higher cost and results in more frequent minor complications but is curative.

Nonconventional imaging techniques

Because of the ease of accessibility of the esophagus, it has been an area of intense research for different imaging techniques. Narrow-band imaging (NBI) is based on using interference filters for the illumination of the mucosa with narrowed blue and green bands of the light spectrum in combination with magnifying endoscopy. It better visualizes and discriminates between the mucosal glandular structures and vascular architecture, when compared with standard resolution white light endoscopy. NBI is better in detecting HGD with a less number of biopsies, and the sensitivity of NBI for HGD in BE was found to be 86%. A simplified classification of mucosal morphology has been validated and found to have a good correlation with histological diagnosis (88%) and good reproducibility regardless of the expertise with NBI use. Confocal laser microscopy (CLM) is mainly used to examine a small segment of the mucosa as opposed to other modalities where the whole esophagus can be examined. A large prospective German study conducted in two phases to establish the criteria for the diagnosis of neoplasia in cases of normal macroscopic appearing mucosa in patients with BE showed that compared with standard high resolution endoscopy (HRE), CLM had a higher negative predictive value (98.8%) for neoplasia in BE but had a poor positive predictive value (44%), these results need further validation on a larger scale. A number of studies have proven that capsule endoscopy is inadequate in the investigation of patients with suspected BE or esophageal disease in general. Magnification chromoendoscopy is able to detect IM in BE. The sensitivity of HRE with indigo carmine chromoendoscopy for HGD in BE is in the range of 93%, whereas using 0.05% crystal violet had a sensitivity of 89% and a specificity of 86%. Computed virtual chromoendoscopy (CVC) is a new imaging modality that enhances the mucosal surface using contrast and delineates the vascular pattern, it has been demonstrated to be as sensitive as conventional chromoendoscopy and with a positive predictive value of only 39%. Another method utilizes autofluorescence endoscopy (AFE) for targeted biopsies in the surveillance of BE. In a multicenter study, AFE was shown to improve the diagnostic yield for neoplasia in comparison with 4QB but was not suitable for replacing the standard 4QB method. Also light-induced fluorescence endoscopy did not enhance the detection of HGD. Although an initial study suggested that magnification endoscopy was superior to standard 4QB in detecting HGD, a second prospective randomized trial showed that there was no added advantage in using enhanced magnification endoscopy in the surveillance of BE.
possible explanation of these apparent discordances in the results is the high interobserver variability and mismatch between cardiac mucosa and nondysplastic Barrett’s mucosa. [123] Raman spectroscopy is based on the principle of inelastic scattering of monochromatic light usually from a laser; it has a promising role in being an adjunct in the surveillance of patients with BE but is still under evaluation, as is optical coherence tomography.[122]

**CURRENT STATUS OF PRACTICE**

A number of guidelines have been issued from different societies regarding the diagnosis and management of patients with BE. [124,125] However, even with the widespread dissemination of these guidelines, our practice in the management of BE is far from perfect and studies have demonstrated wide variations between gastroenterologist practices in the management of BE and the guidelines issued. [126-131]

**FUTURE TRENDS**

The hope is that we can better characterize factors that promote the development of BE and its progression to HGD and EAC and evaluate different biomarkers that can identify this subset of patients. Also there have been efforts toward developing a vaccine for esophageal cancer, with promising results. [132,133] Also the efficacy of Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett’s esophagus. World J Gastroenterol 2005;11:7436-43.

Kim SW, Jang TJ, Jung KH, Suh JI. Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats. Yonsei Med J 2007;48:1020-7.

Mehta SP, Boddy AP, Cook J, Sams V, Lund EK, Johnson IT, et al. Effect of n3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus. Am J Clin Nutr 2008;87:949-56.

Babu A, Meng X, Banerjee AM, Gamboni-Robertson F, Cleveland JC, Damle S, et al. Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model. J Thorac Cardiovasc Surg 2008;135:1220-7.

Triadafilopoulos G, Kaur B, Sood S, Traxler B, Levine D, Weston A. The effects of esomepzparelumborne with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett’s oesophagus. Aliment Pharmacol Ther 2006;23:997-1005.

Corney DA, Kerlikowske K, Verma R, Baffier P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 2003;124:47-56.

Lanas A, Ortego J, Sopena F, Alcedo J, Barrio E, Bujanda L, et al. Effects of longterm cyclooxygenase-2 selective and acid inhibition on Barrett's oesophagus. Aliment Pharmacol Ther 2007;26:913-23.

Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: Results of a randomized trial. J Natl Cancer Inst 2007;99:545-57.

Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett’s oesophageal adenocarcinoma cells. Am J Gastroenterol 2008;103:825-37.

Beales IL, Ogunwobi O, Cameron E, Alamin K, Mutungi G, Wilkinson M. Activation of Akt is increased in the dysplasiascarcinoma sequence in Barrett’s esophagus and contributes to increased proliferation and inhibition of apoptosis: A histopathological and functional study. BMC Cancer 2007;7:97.

Boulou J, Roberts K, Brooks MG, Hughes S, Bury J, Cross SS, et al. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res 2008;14:379-87.

Modiano N, Gerson LB. Barrett’s esophagus: Incidence, etiology, pathophysiology, prevention and treatment. Ther Clin Risk Manag 2007;3:1035-145.

Sollano JD, Wong SN, AndalGumtan T, Chan MM, Carpio RE, Tady CS, et al. Erosive esophagitis in the Philippines: A comparison between two time periods. J Gastroenterol Hepatol 2007;22:1650-5.

Kim JH, Rhee PL, Lee JH, Lee H, Choi YS, Son HJ, et al. Prevalence and

**REFERENCES**

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6.

2. Wang KK, Sampiner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97.

3. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampiner R, Spechler S, et al. A critical review of the diagnosis and management of Barrett’s esophagus: The AGA Chicago Workshop. Gastroenterology 2004;127:310-30.

4. Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008;14:3216-22.

5. Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, et al. Cyclooxygenase 2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008;17:727-31.

6. Sarosi G, Brown G, Jaiswal K, Feagins LA, Lee E, Crook TW, et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus. Dis Esophagus 2008;21:43-50.

7. Buttar NS, Wang KK, Leontovich O, Westcott JY,Pacifico R, Anderson MA, et al. Chemoprevention of esophageal adenocarcinoma by COX2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-2.

8. Piazuelo E, Cebrian C, Escartín A, Jimenez P, Soteras F, Ortego J, et al. Raman spectroscopy is based on the principle of inelastic scattering of monochromatic light usually from a laser; it has a promising role in being an adjunct in the surveillance of patients with BE but is still under evaluation, as is optical coherence tomography.[122]

9. Kim SW, Jang TJ, Jung KH, Suh JI. Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats. Yonsei Med J 2007;48:1020-7.

10. Mehta SP, Boddy AP, Cook J, Sams V, Lund EK, Johnson IT, et al. Effect of n3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus. Am J Clin Nutr 2008;87:949-56.

11. Babu A, Meng X, Banerjee AM, Gamboni-Robertson F, Cleveland JC, Damle S, et al. Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model. J Thorac Cardiovasc Surg 2008;135:1220-7.

12. Triadafilopoulos G, Kaur B, Sood S, Traxler B, Levine D, Weston A. The effects of esomepzparelumborne with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett’s oesophagus. Aliment Pharmacol Ther 2006;23:997-1005.

13. Corley DA, Kerlikowske K, Verma R, Baffier P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 2003;124:47-56.

14. Lanas A, Ortego J, Sopena F, Alcedo J, Barrio E, Bujanda L, et al. Effects of longterm cyclooxygenase-2 selective and acid inhibition on Barrett's oesophagus. Aliment Pharmacol Ther 2007;26:913-23.

15. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: Results of a randomized trial. J Natl Cancer Inst 2007;99:545-57.

16. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett’s oesophageal adenocarcinoma cells. Am J Gastroenterol 2008;103:825-37.

17. Beales IL, Ogunwobi O, Cameron E, Alamin K, Mutungi G, Wilkinson M. Activation of Akt is increased in the dysplasiascarcinoma sequence in Barrett’s esophagus and contributes to increased proliferation and inhibition of apoptosis: A histopathological and functional study. BMC Cancer 2007;7:97.

18. Boulou J, Roberts K, Brooks MG, Hughes S, Bury J, Cross SS, et al. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res 2008;14:379-87.

19. Modiano N, Gerson LB. Barrett’s esophagus: Incidence, etiology, pathophysiology, prevention and treatment. Ther Clin Risk Manag 2007;3:1035-145.

20. Sollano JD, Wong SN, AndalGumtan T, Chan MM, Carpio RE, Tady CS, et al. Erosive esophagitis in the Philippines: A comparison between two time periods. J Gastroenterol Hepatol 2007;22:1650-5.

21. Kim JH, Rhee PL, Lee JH, Lee H, Choi YS, Son HJ, et al. Prevalence and
risk factors of Barrett’s esophagus in Korea. J Gastroenterol Hepatol 2007;22:908-12.

22. van Kerkhoven LA, van Rijswijck SJ, van Rossum LG, Laheij RJ, Witteman EM, Tan AC, et al. Openaccess upper gastrointestinal endoscopy a decade after the introduction of proton pump inhibitors and helicobacter pylori eradication: A shift in endoscopic findings. Digestion 2007;75:227-31.

23. Aldulaimi DM, Cox M, Nwokolo CU, loft DE. Barrett’s surveillance is worthwhile and detects curable cancers: A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol 2005;17:943-50.

24. Jankowski JA, Anderson M. Review article: Management of oesophageal adenocarcinoma control of acid, bile and inflammation in intervention strategies for Barrett’s oesophagus. Aliment Pharmacol Ther 2004;20:71-80.

25. Tseng PH, Lee YC, Chiu HM, Huang SP, Liao WC, Chen CC, et al. Prevalence and clinical characteristics of Barrett’s esophagus in a Chinese general population. J Clin Gastroenterol 2008;42:1074-9.

26. Abrams JA, Fields S, Lightdale CJ, Neugut AI. Racial and ethnic disparities in the prevalence of Barrett’s esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol 2008;6:30-4.

27. Yousef S, Cardwell C, Cantwell MM, galway K, JohnSTon B, Murray L. The incidence of esophageal cancer and high grade dysplasia in Barrett’s esophagus: A systematic review and metaanalysis. Am J Epidemiol 2008;168:237-49.

28. Rastogi A, Pull S, El Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high grade dysplasia: a metaanalysis. Gastrointest Endosc 2008;67:394-8.

29. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: Cancer risk in Barrett’s oesophagus. Aliment Pharmacol Ther 2007;26:1465-77.

30. Kubo A, Levin TR, Block G, Rumore GJ, Quesenberry CP Jr, buffler P, et al. Dietary patterns and the risk of Barrett’s esophagus. Am J Epidemiol 2008;167:839-46.

31. Switzer-Taylor V, Schlup M, Lubcke R, Livingstone V, Schultz M. Barrett’s esophagus: A retrospective analysis of 13 years surveillance. J Gastroenterol Hepatol 2008.

32. Gatenby PA, Caygill CP, Ramus JR, Charlett A, Watson A. Barrett’s oesophagus: Demographic and lifestyle associations and adenocarcinoma risk. Dig Dis Sci 2008;53:1175-85.

33. Eloubeldi MA, Provenzale D. Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: A multivariable analysis in veterans. J Clin Gastroenterol 2001;33:306-9.

34. Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett’s esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol 2001;96:2005-12.

35. Conio M, Filiberti R, Blanchi S, Ferraris R, Marchi S, Ravelli P, et al. Risk factors for Barrett’s esophagus: A case control study. Int J Cancer 2002;97:225-9.

36. Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D. A systematic review and metaanalysis of the risk of increasing adiposity on Barrett’s esophagus. Am J Gastroenterol 2008;103:292-300.

37. Moayyedi P, Burch N, Akhtar Danesh N, Enaganti SK, Harrison R, Talley NJ, et al. Mortality rates in patients with Barrett’s esophagus. Aliment Pharmacol Ther 2008;27:316-20.

38. Cook MB, Wild CP, Everett SM, Hardie LJ, BaniHani KE, Martin IG, et al. Risk of mortality and cancer incidence in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2007;16:2090-6.

39. Peters FT, Kuipers EJ, Ganesh S, Sluiter WJ, KlinkenbergKnoel EC, Lamers CB, et al. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999;13:921-6.

40. Rokkas T, Pistolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: A metaanalysis. Clin Gastroenterol Hepatol 2007;5:1413-7.

41. Harrison R, Perry I, Haddadin W, McDonald S, Bryan R, Abrams K, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: The Prague C and M criteria. Gastroenterology 2006;131:1392-9.

42. Horwhat JD, Maydonovitch CL, Ramos F, Colina R, Gaertner E, Lee H, et al. A randomized comparison of methylene blue directed biopsy versus conventional four quadrant biopsy for the detection of intestinal metaplasia and dysplasia in patients with longsegment Barrett’s esophagus. Am J Gastroenterol 2008;103:546-54.

43. Lim CH, Rotimi O, Dexter SP, Akin AT. Randomized crossover study that used methylene blue or random 4quadrant biopsy for the diagnosis of dysplasia in Barrett’s esophagus. Gastrointest Endosc 2006;64:195-9.

44. Ragunath K, Krasner N, Raman VS, Haqqani MT, Cheung WY. A randomized, prospective crossover trial comparing methylene bluedirected biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett’s esophagus. Endoscopy 2003;35:998-1003.

45. Wo JM, Ray MB, MayfieldStokes S, Al Sabbagh G, Gebrael F, Snelle SP, et al. Comparison of methylene bluedirected biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett’s esophagus: A preliminary study. Gastrointest Endosc 2001;54:294-301.

46. Jego M, Volant A, Faycal J, Doucet L, Andlauer E, Delalande AH, et al. Prevalence and topography of intestinal metaplasia in columnar lined esophagus. Gastroenterol Clin Biol 2007;31:601-6.

47. Downskelly E, Mendelin JE, Bennett AE, Castilla E, Henricks WH, Schoenfield L, et al. Poor interobserver agreement in the distinction of high grade dysplasia and adenocarcinoma in pretreatment Barrett’s esophagus biopsies. Am J Gastroenterol 2008;103:2333-40.

48. Harrison R, Perry I, Haddadin W, McDonald S, Bryan R, Abrams K, et al. Detection of intestinal metaplasia in Barrett’s esophagus: An observational comparator study suggests the need for a minimum of...
eight biopsies. Am J Gastroenterol 2007;102:1154-61.

56. Abele JE, Going JJ, Mackenzie JF, McKernan M, O'Mahoney S, Stuart RC. Systematic four quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008;103:850-5.

57. Levine DS, Reid BJ. Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc 1991;37:332-7.

58. Dolwani S, Saleem H, Thompson IW, Allison MC. A comparison of three types of biopsy forcesps in the endoscopic surveillance of Barrett's oesophagus. Endoscopy 2002;34:946-9.

59. Hage M, Siersema PD, Vissers KJ, Steyerberg EW, Haringsma J, Kuipers EJ, et al. Molecular evaluation of ablative therapy of Barrett's oesophagus. J Pathol 2005;205:57-64.

60. Armstrong D. Should patients with Barrett's oesophagus be kept under surveillance? The case for. Best Pract Res Clin Gastroenterol 2008;22:721-39.

61. Barritt AS, Shaheen NJ. Should patients with Barrett's oesophagus be kept under surveillance? The case against. Best Pract Res Clin Gastroenterol 2008;22:741-50.

62. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: A population based study. Gastroenterology 2002;122:633-40.

63. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high grade dysplasia. Am J Gastroenterol 2000;95:3089-96.

64. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Intragastric esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: A randomized, three way crossover study. Aliment Pharmacol Ther 2004;20:399-406.

65. Spechler SJ, Sharma P, Traxler B, Levine D, Falk GW. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: A randomized, double blind, crossover trial. Am J Gastroenterol 2006;101:1964-71.

66. Attwood SE, Lundell L, Hatlebakk JG, Eklund S, Junghard O, Galmiche JP, et al. Medical or surgical management of GERD patients with Barrett's esophagus: The LOTUS trial 3 year experience. J Gastrointest Surg 2008;12:1646-54.

67. Porrilla P, Martinez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, et al. Longterm results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003;237:291-8.

68. Li YM, Li L, Yu CH, Liu YS, Xu CF. A systematic review and meta analysis of the treatment for Barrett's esophagus. Dig Dis Sci 2008;53:2837-46.

69. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004;180:387-91.

70. El Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877-83.

71. Braghetto I, Papapietro K, Csendes A, Gutierrez J, Fagade P, Diaz E, et al. Nonsophageal side effects after antireflux surgery plus acid-suppression duodenal diversion surgery in patients with longsegment Barrett's esophagus. Dis Esophagus 2005;18:140-5.

72. Pacifico RJ, Wang KK, Wongkeesong LM, Buttar NS, Lutzke LS. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003;1:252-7.

73. Pech O, May A, Gossner L, Eil C. Barrett's esophagus: Endoscopic resection. Gastrointest Endosc Clin N Am 2003;13:505-12.

74. Yachimski P, Nishioka NS, Richards E, Hur C. Treatment of Barrett's esophagus with high grade dysplasia or cancer: Predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol 2008;6:1206-11.

75. Williams VA, Watson TJ, Herberla FA, Gellersen O, Raymond D, Jones C, et al. Esophagectomy for high grade dysplasia is safe, curative and results in good alimentary outcome. J Gastrointest Surg 2007;11:1589-97.

76. Low DE, Kunz S, Scheibler D, Otter H, Malpaas T, Hsi A, et al. Esophagomycytis not just about mortality anymore: Standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. J Gastrointest Surg 2007;11:1395-402.

77. Peyre CG, DeMeester SR, Rizzetto C, Bansal N, Tang AL, Ayazi S, et al. Vagalsparing esophagectomy: The ideal operation for intramucosal adenocarcinoma and Barrett with high grade dysplasia. Ann Surg 2007;246:665-71.

78. Wolfson HC. Endoprevention of esophageal cancer: Endoscopic ablation of Barrett's metaplasia and dysplasia. Expert Rev Med Devices 2005;2:713-23.

79. Faybush EM, Sampliner RE. Randomized trials in the treatment of Barrett's esophagus. Dis Esophagus 2005;18:291-7.

80. Sharma P, Wani S, Weston AP, Bansal A, Hall M, Mathur S, et al. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: Long term results. Gut 2006;55:1233-9.

81. Dolai GS, Jensen DM, Cortina G, Fontana L, Ippoliti A. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc 2005;61:232-40.

82. Kelty CJ, Ackroyd RD, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Endoscopic ablation of Barrett's oesophagus: A randomised controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004;11:1289-96.

83. Ackroyd R, Tam W, Schoeman M, Devitt PG, Watson DJ. Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery. Gastrointest Endosc 2004;59:17.

84. Ragunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung DV. Endoscopic ablation of Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: A randomized prospective trial assessing efficacy and cost effectiveness. Scand J Gastroenterol 2005;40:750-8.

85. Hage M, Siersema PD, van Dekken H, Steyerberg EW, van Hasselt KV, van der Sluijs AP, Raesel A, Halkes M, et al. Endoscopic ablation of dysplastic Barrett's oesophagus comparing photodynamic therapy with argon plasma coagulation: A randomized controlled trial. Gastrointest Endosc Clin N Am 2003;13:483-9, vii.

86. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:4839, vii.

87. Wolfsen HC. Endoprevention of esophageal cancer: Endoscopic ablation of Barrett's metaplasia and dysplasia. Expert Rev Med Devices 2005;2:713-23.
of highgrade dysplasia in Barrett's esophagus: International, partially blinded, randomized phase III trial. Gastroint Endosc 2005;62:488-98.

91. Yachimski P, Puricelli WP, Nishioka NS. Patient predictors of esophageal stricture development after photodynamic therapy. Clin Gastroenterol Hepatol 2006;6:302-8.

92. Prasad GA, Wang KK, Buttar NS, Wongkeesong LM, Lutzke LS, Borkenhagen LS. Predictors of stricture formation after photodynamic therapy for high grade dysplasia in Barrett's esophagus. Gastroint Endosc 2007;65:60-6.

93. Larghi A, Lightdale CJ, Ross AS, Fedi P, Hart J, Rotterdam H, et al. Longterm followup of complete Barrett's eradication endoscopic mucosal resection (CBEEMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy 2007;39: 1086-91.

94. Abrams JA, Fedi P, Vakiani E, Hatefi D, Remotti HE, Lightdale CJ. Depth of resection using two different endoscopic mucosal resection techniques. Endoscopy 2008;40:395-9.

95. Owens MM, Kimney MB. The role of endoscopic ultrasound in the diagnosis and management of Barrett's esophagus. Gastroint Endosc Clin N Am 2003;13:325-34.

96. MinoKenudson M, Brugge WR, Puricelli WP, Nakatsuka LN, Nishioka NS, Zukerberg LR, et al. Management of superficial Barrett's epitheliumrelated neoplasms by endoscopic mucosal resection: Clinicopathologic analysis of 27 cases. Am J Surg Pathol 2005;29:680-6.

97. MinoKenudson M, Hull MJ, Brown I, Muzikansky A, Srivastava A, Glickman J, et al. EMR for Barrett's esophagusrelated superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastroint Endosc 2007;66:660-6.

98. Prasad GA, Buttar NS, Wongkeesong LM, Lewis JT, Sanderson SO, Lutzke LS, et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol 2007;102:2380-6.

99. Hernandez JC, Reicher S, Chung D, Pham BV, Tsai F, Disibio G, et al. Pilot series of radiofrequency ablation of Barrett's esophagus with or without neoplasia. Endoscopy 2008;40:388-92.

100. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus 2007;20:516-22.

101. Hubbard N, Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus in patients with fundoplications. Surg Endosc 2007;21:625-8.

102. Sharma VK, Wang KK, Overholt BF, Lightdale CJ, Fennerty MB, Dean PJ, et al. Balloonbased, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1 year followup of 100 patients. Gastroint Endosc 2007;65:185-95.

103. Ganz RA, Overholt BF, Sharma VK, Fleischer DE, Shaheen NJ, Lightdale CJ, et al. Circumferential ablation of Barrett's esophagus that contains highgrade dysplasia: A U.S. Multicenter Registry. Gastroint Endosc 2008;68:35-40.

104. Fleischer DE, Overholt BF, Sharma VK, Reymunde A, Kimmey MB, Chuttani R, et al. Endoscopic ablation of Barrett's esophagus: A multicenter study with 2.5year followup. Gastroint Endosc 2008;68:876-77.

105. Schembre DB, Huang JL, Lin OS, Cantone N, Low DE. Treatment of Barrett's esophagus with early neoplasia: A comparison of endoscopic therapy and esophagectomy. Gastroint Endosc 2008;67:595-601.

106. Lambert R, Kuznetsov K, Rey JF. Narrowband imaging in digestive endoscopy. Scientific World Journal 2007;7:449-65.

107. Wolfsen HC, Crook JE, Krishna M, Achem SR, Devault KR, Bouras EP, et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's Esophagus. Gastroenterology 2008;135:24-31.

108. Anagnostopoulou G, Yag K, Kaye P, Hawkey CJ, Ragnath K. Novel endoscopic observation in Barrett's esophagus using high resolution magnification endoscopy and narrow band imaging. Aliment Pharmacol Ther 2007;26:501-7.

109. Kara MA, Peters FP, Rosmolen WD, Krishnadath KK, ten Kate FJ, Fockens P, et al. High resolution endoscopy plus chromoendoscopy or narrowband imaging in Barrett's esophagus: A prospective randomized crossover study. Endoscopy 2005;37:929-36.

110. Singh R, Anagnostopoulou G, Yag K, Karageorgiou H, Fortun PJ, Shonde A, et al. Narrowband imaging with magnification in Barrett's esophagus: Validation of a simplified grading system of mucosal morphology patterns against histology. Endoscopy 2008;40:457-63.

111. Pohl H, Roesch T, Vieth M, Koch M, Becker V, Andres M, et al. Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's esophagus. Gut 2008 [Epub ahead of print].

112. Qureshi WA, Wu J, Demarco D, Abudayyeh S, Graham DY. Capsule endoscopy for screening for shortsegment Barrett's esophagus. Am J Gastroenterol 2008;103:533-7.

113. Delvaux M, Papanikolaou IS, Fassler I, Pohl H, Voderholzer W, Rosch T, et al. Esophageal capsule endoscopy in patients with suspected esophageal disease: Double blinded comparison with esophagogastroduodenoscopy and assessment of interobserver variability. Endoscopy 2008;40:16-22.

114. Reaud S, Croue A, Beyer J. Diagnostic accuracy of magnifying chromoendoscopy with detection of intestinal metaplasia and dysplasia using acetic acid in Barrett's esophagus. Gastroenterol Clin Biol 2006;30:217-23.

115. Amano Y, Kusihyama Y, Ishihara S, Yuki T, Myaoka Y, Yoshino N, et al. Crystal violet chromoendoscopy with mucosal pit pattern diagnosis is useful for surveillance of short segment Barrett's esophagus. Am J Gastroenterol 2005;100:21-6.

116. Pohl J, May A, Rabenstein T, Pech O, Nguyen Tat M, Fissler Eckhoff A, et al. Comparison of computed virtual chromoendoscopy and conventional chromoendoscopy with acetic acid for detection of neoplasia in Barrett's esophagus. Endoscopy 2007;39:594-8.

117. Boruvcka J, Fischer J, Neuweiler J, Netzer P, Gschossmann J, Ehmann T, et al. Autofluorescence endoscopy in surveillance of Barrett's esophagus: A multicenter randomized trial on diagnostic efficacy. Endoscopy 2006;38:867-72.

118. Kara MA, Smits ME, Rosmolen WD, Bultje AC, ten Kate FJ, Fockens P, et al. A randomized crossover study comparing light induced fluorescence endoscopy with standard videodeendoscopy for the detection of early neoplasia in Barrett's esophagus. Gastroint Endosc 2005;61:671-8.

119. Hoffmann A, Kiessler B, Benda A, Neurath MF, Nafe B, Herrmann G, et al. Acetic acidguided biopsies after magnifying endoscopy compared with random biopsies in the detection of Barrett's esophagus: A prospective randomized trial with crossover design. Gastroint Endosc 2006;64:18.

120. Ferguson DD, Devault KR, Krishna M, Loeb DS, Wolfsen HC, Wallace MB. Enhanced magnificationdirected biopsies do not increase the detection of intestinal metaplasia in patients with GERD. Am J Gastroenterol 2006;101:1611-6.

121. Mayinger B, Oezturk Y, Stolte M, Faller G, Benninger J, Schwab D, et al. Endoscopic ablation of Barrett's esophagus: A U.S. Multicenter Registry. Gastroint Endosc 2008;68:867-76.

122. Hoffman A, Kiessler B, Benda A, Neurath MF, Nafe B, Herrmann G, et al. Acetic acidguided biopsies after magnifying endoscopy compared with random biopsies in the detection of Barrett's esophagus: A prospective randomized trial with crossover design. Gastroint Endosc 2006;64:18.
122. DaCosta RS, Wilson BC, Marcon NE. Fluorescence and spectral imaging. Scientific World Journal 2007;7:2046-71.
123. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2006;103:788-97.
124. SSAT patient care guidelines. Management of Barrett's esophagus. J Gastrointest Surg 2007;11:1213-5.
125. Boyer J, Laugier R, Chemali M, Arpurt JP, Boustiere C, Canard JM, et al. French Society of Digestive Endoscopy SFED guideline: Monitoring of patients with Barrett's esophagus. Endoscopy 2007;39:840-2.
126. Das D, Ishaq S, Harrison R, Kosuri K, Harper E, Decaestecker J, et al. Management of Barrett's esophagus in the UK: Over treated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol 2008;103:1079-89.
127. Amamra N, Touzet S, Colin C, Ponchon T. Current practice compared with the international guidelines: Endoscopic surveillance of Barrett's esophagus. J Eval Clin Pract 2007;13:789-94.
128. Abdalla AA, Petersen BT, Ott BJ, Fredericksen M, Schleck CD, Zinsmeister AR, et al. Impact of feedback and didactic sessions on the reporting behavior of upper endoscopic findings by physicians and nurses. Clin Gastroenterol Hepatol 2007;5:326-30.
129. Bampton PA, Schloithe A, Bull J, Fraser RJ, Padbury RT, Watson DI. Improving surveillance for Barrett's oesophagus. BMJ 2006;332:1320-3.
130. MacNeil Covin L, Casson AG, Malatjalian D, Veldhuysen VZ. A survey of Canadian gastroenterologists about the management of Barrett's esophagus. Can J Gastroenterol 2003;17:313-7.
131. Mandal A, Playford RJ, Wicks AC. Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. Aliment Pharmacol Ther 2003;17:1319-24.
132. Miyashita T, Shah FA, Marti G, Wang J, Armstrong T, Bonde P, et al. Vaccine impedes the development of refluxinduced esophageal cancer in a surgical rat model: efficacy of the vaccine in a PreBarrett's esophagus setting. J Gastrointest Surg 2008;12:27.
133. Miyashita T, Shah FA, Marti GP, Armstrong TD, Wang J, Bonde P, et al. Vaccine impedes the development of Reflux induced esophageal cancer in a surgical rat model: Efficacy of the vaccine in a PostBarrett's esophagus setting. Dig Dis Sci 2008;53:2858-67.
134. Anagnostopoulos GK, Pick B, Cunliffe R, Fortun P, Kaye P, Ragunath K. Barrett's esophagus specialist clinic: What difference can it make? Dis Esophagus 2006;19:84-7.
135. Jobe BA, Hunter JG, Chang EY, Kim CY, Eisen GM, Robinson JD, et al. Officebased unsedated smallcaliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: A randomized and blinded comparison. Am J Gastroenterol 2006;101:2693-703.
136. Atkinson M, Das A, Faulx A, Kinnard M, Falck-Ytter Y, Chak A. Ultrathin esophagoscopy in screening for Barrett's esophagus at a Veterans Administration Hospital: Easy access does not lead to referrals. Am J Gastroenterol 2008;103:92-7.

**Source of Support:** Nil, **Conflict of Interest:** None declared.